Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2).
On January 16, 2024, the Company received a written notice from Nasdaq stating that the Company’s Market Value of Listed Securities has been $35 million or greater for ten consecutive business days from January 2 to January 16, 2024, and therefore the Company has regained compliance with the MVLS requirement for continued listing on the Nasdaq Capital Market.
For investor and media inquiries, please contact:
Dr. Kelvin Chen
Chief Executive Officer
EUDA Health Holdings Limited
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.19 |
| Daily Change: | -0.12 -2.78 |
| Daily Volume: | 100,317 |
| Market Cap: | US$147.190M |
May 06, 2024 November 23, 2022 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
